Presentation is loading. Please wait.

Presentation is loading. Please wait.

Background: Gene Expression

Published byPreston Ryan Modified over 5 years ago

Similar presentations

Presentation on theme: "Background: Gene Expression"— Presentation transcript:

1

2 Background: Gene Expression
Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

3 Methods: Phase II Trial
Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

4 Methods: Gene Expression
Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

5 CHT Slide 9 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

6 Slide 10 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

7 Slide 11 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

8 Slide 12 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

9 Slide 13 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

10 Slide 15 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

11 Conclusions: Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

12 Slide 18 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

13 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Comparative effectiveness of adjuvant chemotherapy versus observation in patients with ≥ pT3 and/or pN+ bladder cancer Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

14 Randomized Trials of Adjuvant Therapy
Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

15 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Study Overview Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

16 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Methods - I Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

17 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Methods - II Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

18 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Study Cohort Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

19 Variables associated with treatment selection
Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

20 Effect of adjuvant chemotherapy on hazard ratio for overall survival
Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

21 Impact of adjuvant chemotherapy on overall survival in patient subsets
Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

22 Analyses of adjuvant chemotherapy
Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

23 Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium
Conclusions Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Download ppt "Background: Gene Expression"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advances and Emerging Therapy for Lung Cancer

Advances and Emerging Therapy for Lung Cancer
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
One good example of considering gene expressions at the review for approval Taxol: Indicated for the adjuvant treatment of node- positive breast cancer.

One good example of considering gene expressions at the review for approval Taxol: Indicated for the adjuvant treatment of node- positive breast cancer.
Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.

Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.
Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB 80203.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < 0.0001(Log-rank) a Months Low gene expression.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.
Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.
1 BLA 1251970 Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.

1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Similar presentations

Ads by Google